These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


192 related items for PubMed ID: 8345288

  • 21. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH, Howes J.
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [Abstract] [Full Text] [Related]

  • 22. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M, Busin M.
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [Abstract] [Full Text] [Related]

  • 23. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ, Shulman DG, Lowry GM, Howes J.
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [Abstract] [Full Text] [Related]

  • 24. Effect of Topical Periocular Steroid Use on Intraocular Pressure: A Retrospective Analysis.
    Maeng MM, De Moraes CG, Winn BJ, Glass LRD.
    Ophthalmic Plast Reconstr Surg; 2019 Jun; 35(5):465-468. PubMed ID: 30730433
    [Abstract] [Full Text] [Related]

  • 25. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation.
    Howes JF, Baru H, Vered M, Neumann R.
    J Ocul Pharmacol; 1994 Jun; 10(1):289-93. PubMed ID: 8207332
    [Abstract] [Full Text] [Related]

  • 26. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
    Vittitow JL, Williams JI.
    J Cataract Refract Surg; 2020 Aug; 46(8):1092-1101. PubMed ID: 32352250
    [Abstract] [Full Text] [Related]

  • 27. Comparison of ophthalmic loteprednol etabonate and prednisolone acetate effects on adrenocortical response to ACTH in dogs.
    Kline KE, Walton SA, Specht AJ, Santoro D, Watson TJ, Eide ML, Opgenorth TA, Plummer CE.
    Vet Ophthalmol; 2022 Nov; 25(6):468-475. PubMed ID: 35913421
    [Abstract] [Full Text] [Related]

  • 28. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids.
    Leibowitz HM, Bartlett JD, Rich R, McQuirter H, Stewart R, Assil K.
    Arch Ophthalmol; 1996 Aug; 114(8):933-7. PubMed ID: 8694727
    [Abstract] [Full Text] [Related]

  • 29. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K.
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [Abstract] [Full Text] [Related]

  • 30. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S, Goa KL.
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [Abstract] [Full Text] [Related]

  • 31. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B.
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [Abstract] [Full Text] [Related]

  • 32. Prevention of corticosteroid-induced intraocular pressure elevation using ISV-205.
    Stewart WC, ISV-205 Study Group.
    Arch Ophthalmol; 2003 Nov; 121(11):1543-7. PubMed ID: 14609909
    [Abstract] [Full Text] [Related]

  • 33. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.
    Chen M, Gong L, Sun X, Gu Y, He X, Qu J, Wang L, Zhang M, Zhong X.
    Curr Med Res Opin; 2012 Mar; 28(3):385-94. PubMed ID: 22256909
    [Abstract] [Full Text] [Related]

  • 34. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.
    Oner V, Türkcü FM, Taş M, Alakuş MF, Işcan Y.
    Jpn J Ophthalmol; 2012 Jul; 56(4):312-8. PubMed ID: 22622345
    [Abstract] [Full Text] [Related]

  • 35. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids.
    Bartlett JD, Woolley TW, Adams CM.
    J Ocul Pharmacol; 1993 Jul; 9(1):35-45. PubMed ID: 8463731
    [Abstract] [Full Text] [Related]

  • 36. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
    Price MO, Feng MT, Price FW.
    Am J Ophthalmol; 2021 Feb; 222():382-387. PubMed ID: 33045216
    [Abstract] [Full Text] [Related]

  • 37. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N, Bodor N, Wu WM.
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
    Rajpal RK, Fong R, Comstock TL.
    Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children.
    Yoo YJ, Yang HK, Hwang JM.
    J Ocul Pharmacol Ther; 2018 Oct; 34(6):468-476. PubMed ID: 29958057
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 10.